What this pack is
PAXLOVID is the brand name in this record; nirmatrelvir and ritonavir is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
PAXLOVIDGeneric namenirmatrelvir and ritonavir
How this medicine works
The U.S. PAXLOVID label describes nirmatrelvir as an inhibitor of the SARS-CoV-2 main protease and ritonavir as an HIV-1 protease inhibitor and CYP3A inhibitor. This explains labelled pharmacologic pathways; it does not decide anyone's infection, risk, suitability, use arrangement or outcome with another medicine.
Read source: United States ↗Current regulatory record · reviewed 2026-08-20More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- PAXLOVID
- Generic name
- nirmatrelvir and ritonavir
- Dosage-form class
- Co-packaged nirmatrelvir tablets and ritonavir tablets for oral use (as listed in the U.S. public label)
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
The two component names, tablet counts and blister-card structure identify one cited co-pack. They do not select a renal-related pack or create a self-directed tablet, timing, interaction, stopping or substitution plan.
1 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · DailyMed SPL v12, published 23 Feb 2026
Nirmatrelvir 150 mg × 2 + ritonavir 100 mg × 1; 3-tablet blister card
- Product code
- NDC 0069-5045-06
- Form and route
- PAXLOVID nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use · oral
- Container
- blister card
- Units in each inner container
- 3 tablets per blister cardPackage identity only; not an individual amount to take
- nirmatrelvir
- 150 mglabelled amount in each nirmatrelvir tablet; not an individual's tablet count or use plan
- ritonavir
- 100 mglabelled amount in each ritonavir tablet; not an individual's tablet count or use plan
- Package
- 1 blister card per pack
PUBLIC LABEL IMAGE
Appearance and package-text clues
This dated or historical public-label image is for checking the brand, generic-name, strength and dosage-form clues only. It does not authenticate a product or establish originator status, a current label, current packaging, target-market approval or sale eligibility.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
PAXLOVID label reading: check both ingredients, the co-packaged product and the complete medicine list together
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module uses the current U.S. DailyMed public label to check PAXLOVID, nirmatrelvir/ritonavir, the co-packaged oral tablets, the exact package panel and target market. It provides no individual tablet count, start time, renal plan, missed-use remedy, co-use, stopping or switching plan.
- PAXLOVID is a co-packaged two-ingredient product. Component names, milligram markings or tablet appearance on the pack do not justify self-separating, making up, substituting or adjusting one part with another medicine at home; have the exact prescription, actual pack and current label reviewed by a pharmacist or prescribing team.
- The page image corresponds only to one U.S. co-packaged panel, NDC 0069-5045-06. The label also contains product information for different renal circumstances; the same brand, similar colour or nirmatrelvir/ritonavir wording does not establish that two packs or their contents can be self-interchanged.
- The U.S. label has a prominent warning about significant drug interactions: ritonavir in PAXLOVID can strongly alter exposure to certain co-medications and may lead to serious, life-threatening or fatal events. Before and during use, have a clinician or pharmacist review every prescription medicine, OTC product and herbal/supplement product item by item; do not self-stop, reduce, increase or separate any long-term medicine because of a webpage, package or another person's experience.
- With breathing difficulty, swelling of the face/lips/tongue, difficulty swallowing, severe rash or another acute serious concern, use local emergency medical support immediately. Questions about COVID-19 symptoms, suitability, timing, kidney function, liver function or interactions still require the local care team to use the exact diagnosis, tests and complete medicine list.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-20
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. PAXLOVID nirmatrelvir/ritonavir co-packaged oral-tablet public label (Pfizer; SPL v12, published 23 Feb 2026) ↗Current regulatory record · reviewed 2026-08-20
Reviewed official safety records
A dated record is not automatically a current alert. Read the named product, form, batch, market, date and source type before treating it as relevant.
- FDA drug alert: U.S. authorisation-status change for EUA-labelled PAXLOVID2024-03-13 · In an update dated 2024-03-13, FDA said that in the U.S. PAXLOVID labelled for EUA use, including product whose labelled or extended expiration information remained, was no longer authorised for emergency use; the notice directs handling of EUA-labelled product in U.S. distribution and distinguishes NDA-approved labelling. This is U.S.-market information for a specific labelling status and date. It does not determine another market, authenticity of any pack, whether an individual should use PAXLOVID, or whether co-medication can be changed independently. Check the actual pack, the current document for its market and the prescribing team or pharmacist.Primary-source record (open linked document) ↗reviewed 2026-08-22
Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about PAXLOVID (nirmatrelvir and ritonavir). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
PAXLOVID is the brand in this record and nirmatrelvir and ritonavir is the active-ingredient name. Check both with the dosage form (Co-packaged nirmatrelvir tablets and ritonavir tablets for oral use (as listed in the U.S. public label)) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
HOW IT WORKS · NOT A TREATMENT PLAN
How PAXLOVID works: the two ingredients have different labelled roles in one co-packaged product
- “Acts on a viral protease” cannot be used by a webpage to decide whether a person needs antiviral treatment, has COVID-19, will improve on their own or should start any product at a particular time. Diagnosis, testing and time-sensitive assessment belong with local medical care.
- Ritonavir's CYP3A inhibition is also why the complete medicine list matters: a mechanism term cannot tell a webpage whether a blood-pressure medicine, lipid medicine, anticoagulant, sedative, herb or supplement should be stopped, reduced, changed or separated. Such decisions must be made by someone reviewing the exact prescription and every product.
- Appearing together on the PAXLOVID label does not make nirmatrelvir, ritonavir or another ritonavir-containing product self-combinable. A shared ingredient, similar package number or past prescription experience cannot replace professional review of this exact co-packaged product and current label.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. PAXLOVID nirmatrelvir/ritonavir co-packaged oral-tablet public label (Pfizer; SPL v12, published 23 Feb 2026) ↗Current regulatory record · reviewed 2026-08-20
SOURCE-TRACEABLE ARCHIVE
PAXLOVIDnirmatrelvir and ritonavir
This page links to public primary-source material for PAXLOVID. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval year listed in the current label
The current PAXLOVID label lists Initial U.S. Approval: 2023. This year locates this U.S. archive only; it does not establish approval, supply, sale eligibility or individual suitability in Mainland China, the EU, Japan or another market.
DailyMed (NLM): current U.S. PAXLOVID nirmatrelvir/ritonavir co-packaged oral-tablet public label (Pfizer; SPL v12, published 23 Feb 2026) ↗Current public SPL v12 published on DailyMed
DailyMed lists 23 Feb 2026 as the publication date for PAXLOVID co-packaged oral-tablet SPL v12. This page selects only one exact 300 mg; 100 mg package panel, NDC 0069-5045-06, and does not establish another pack, a renal-related pack, stock, start time, co-use or individual use.
DailyMed (NLM): current U.S. PAXLOVID nirmatrelvir/ritonavir co-packaged oral-tablet public label (Pfizer; SPL v12, published 23 Feb 2026) ↗
MARKET SCOPE
Market-record boundary
United States
Co-packaged oral-tablet public label and one exact package panel linkedThe displayed panel only corresponds to PAXLOVID nirmatrelvir/ritonavir co-packaged oral tablets, 300 mg; 100 mg, NDC 0069-5045-06. It does not establish actual availability, stock, individual use, a renal plan, co-use, stopping, make-up use or another-pack status.
Mainland China, EU, Japan and other markets
Market record not establishedNo local trade name, approval, packaging, supply, sale eligibility, originator/generic relationship or interchangeability is inferred from the U.S. label or brand name; every market version needs separate checking against current local regulatory information.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
The package names nirmatrelvir and ritonavir. Can another medicine containing one component be used to make up, replace or pair with it?
No. This page establishes only the U.S. public-label reading path for this co-packaged product. A shared component, similar milligram marking or another pack cannot establish self-make-up, separation, combination, replacement, spacing or adjustment; have a pharmacist or prescribing team promptly review the complete medicine list, actual pack and current label.
Why does the PAXLOVID page repeatedly ask for review of all medicines, OTC products and herbs/supplements?
Because the current U.S. label has a prominent warning about significant drug interactions and ritonavir can strongly alter exposure to some co-medications. This prompt does not list or decide which product an individual should stop, change or continue; its purpose is to direct prompt item-by-item professional review.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.